Economic assessment in the management of non-Hodgkin's lymphoma

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 12, 2004, Pages 2529-2548

  van Agthoven, Michel ^a   Uyl de Groot, Carin A ^a   Sonneveld, Pieter ^a   Hagenbeek, Anton ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antineoplastic combined chemotherapy protocols; Cost of illness; Costs and cost analysis; Drug therapy; Economics; Haematological neoplasms; Haematopoietic cell growth factors; Haematopoietic stem cell transplantation; Healthcare costs; Malignant lymphoma; Monoclonal antibodies; Non Hodgkin's lymphoma; Stem cell transplantation

Indexed keywords

ALEMTUZUMAB; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; METHYLPREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TENIPOSIDE; VINCRISTINE SULFATE; VINDESINE;

ADULT; ANEMIA; CLINICAL TRIAL; COCHRANE LIBRARY; COST BENEFIT ANALYSIS; DRUG COST; ECONOMIC EVALUATION; FEVER; HEALTH CARE UTILIZATION; HUMAN; INFECTION; LANGUAGE; MEDICAL LITERATURE; MEDLINE; METHODOLOGY; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PUBLICATION; REVIEW; SENSITIVITY ANALYSIS; THROMBOCYTOPENIA;

ADULT; ANTIBODIES, MONOCLONAL; COSTS AND COST ANALYSIS; EXPERT TESTIMONY; HEALTH CARE COSTS; HUMANS; LYMPHOMA, NON-HODGKIN; STEM CELL TRANSPLANTATION;

EID: 10644275294     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.12.2529     Document Type: Review

References (120)

1. HAUKE RJ, ARMITAGE JO: A new approach to non-Hodgkin's lymphoma. Intern. Med. (2000) 39(3):197-208.
2. ZEEB H, BLETTNER M: Increasing incidence and mortality of non-Hodgkin lymphomas. An epidemiological review of recent studies on risk factors for non-Hodgkin lymphoma. Med. Klin. (Munich) (2001) 96(2):87-100.
3. MELTZER MI: Introduction to health economics for physicians. Lancet (2001) 358:993-998.
4. FREEMAN M, VOSE J, BENNETT C et al.: Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: results ftom the University of Nebraska Medical Center 1989 to 1995. Bone Marrow Transplant. (1999) 24 6):679-684.
5. SCHULMAN K, BURKE J, DRUMMOND M et al.: Resource costing for multinational neurologic clinical trials: methods and results. Health Econ. (1998) 7(7):629-638.
6. ADAM T, KOOPMANSCHAP MA: Cost-effectiveness analysis: can we reduce variability in costing methods? Int. J. Technol. Assess. Health Care (2003) 19(2):407-420.
7. DRUMMOND MF, O'BRIEN B, STODDART GL, TORRANCE GW: Methods for the economic evaluation of health care programs. Oxford University Press, Oxford, UK (1997).
8. GOLD MR, SIEGEL JE, RUSSELL LB, WEINSTEIN MC: Cost-effectiveness in health and medicine. Oxford University Press, New York, USA (1996).
9. FINKLER SA: The distinction between cost and charges. Ann. Intern. Med. (1982) 96(1):102-109.
10. DRUMMOND MF, JEFFERSON TO: Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ(1996) 313(7052):275-283.
11. RYAN MT, SPICER KM, FREI-LAHR D et al.: Health physics consequences of out-patient treatment of non-Hodgkin's lymphoma with 131I-radiolabeled anti-B1 antibody. Health Phys. (2000) 79(5 Suppl.):S52-S55.
12. SCHEID C, DRAUBE A, REISER M et al.: Using at least 5×10(6)/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation. Bone Marrow Transplant. (1999) 23 11):1177-1181.
13. GUIDRY JJ, ADAY LA, ZHANG D, WINN RJ: Cost considerations as potential barriers to cancer treatment. Cancer Pract. (1998) 6 3):182-187.
14. DRANITSARIS G: Treatment of non-Hodgkin's lymphoma. Anticancer Drugs (1998) 9(10):879-888.
15. STAHEL RA, JOST LM, HONEGGER H, BETTS E, GOEBEL ME, NAGLER A: Randomized trial showing equivalent efficacy of filgrastim 5micrograms/kg/d and 10micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas. J. Clin. Oncol. (1997) 15(5):1730-1735.
16. FISHER RI: Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma. Cancer Chemother. Pharmacol. (1997) 40(Suppl.):S42-S46.
17. BOLWELL B, GOORMASTIC M, DANNLEY R et al.: G-CSF post-autologous progenitor cell transplantation: a randomized study of 5, 10, and 16micrograms/kg/day. Bone Marrow Transplant. (1997) 19 3):215-219.
18. FISHER RI, GAYNOR ER, DAHLBERG S et al.: A Phase III comparison of CHOP versus m-BACOD versus ProMACE-CytaBOM versus MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516(Intergroup 0067), the National High-Priority Lymphoma Study. Ann. Oncol. (1994) 5(Suppl. 2):91-95.
19. PETTENGELL R, LINCH D: Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma. Br. J. Haematol. (2003) 121(1):44-48.
20. NO AUTHORS LISTED: Rituximab: new indication. In aggressive non Hodgkin lymphoma: benefits must be confirmed. Prescrire Int. (2003) 12(66):125-126.
21. NUMBENJAPON T, SRISWASDI C, MONGKONSRITRAGOON W, LEELASIRI A, PRAYOONWIWAT W: Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma. J. Med. Assoc. Thai. (2002) 85(11):1156-1163.
22. MIN YJ, KIM SW, SUH C et al.: The possible cost effectiveness of peripheral blood stem cell mobilization with cyclophosphamide and the late addition of G-CSF. J. Korean Med. Sci. (2000) 15(1):49-52.
23. ASTIER MP, MAYORDOMO JI, ABAD JM, GOMEZ LI, TRES A: Cost-analysis of high-dose chemotherapy and peripheral blood stem-cell support in patients with solid tumors. Ann. Oncol. (2000) 11 5):603-606.
24. OJEDA E, GARCIA-BUSTOS J, AGUADO M et al.: A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in adults. Bone Marrow Transplant. (1999) 24(6):601-607.
25. KATH R, HARTMANN M, HOFFKEN K: Pharmacoeconomic evaluation of high-dose chemotherapy and peripheral blood stem cell support in high-risk or poor-prognosis malignancies. J. Cancer Res. Clin. Oncol. (1998) 124(5):288-290.
26. FIREMAN BH, QUESENBERRY CP, SOMKIN CP et al.: Cost of care for cancer in a health maintenance organization. Health Care Financ. Rev. (1997) 18(4):51-76.
27. ELTING LS, CANTOR SB, MARTIN CG et al.: Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer (2003) 97(6):1541-1550.
28. BENNETT CL, STINSON TJ, VOGEL V et al.: Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project. J. Clin. Oncol. (2000) 18(15):2805-2810.
29. CHIRIKOS TN, RUCKDESCHEL JC, KRISCHER JP: Impact of clinical trials on the cost of cancer care. Med. Care (2001) 39 4):373-383.
30. BRICE P, GODIN S, LIBERT O et al.: Effect of lenograstim on the cost of autologous bone marrow transplantation. A preliminary communication. Pharmacoeconomics (1995) 7 3):238-241.
31. QUANTIN C, ENTEZAM F, BRUNET-LECOMTE P, LEPAGE E, GUY H, DUSSERRE L: High cost factors for leukaemia and lymphoma patients: a new analysis of costs within these diagnosis related groups. J. Epidemiol. Community Health (1999) 53(1):24-31.
32. WEAVER CH, WEST W, SCHWARTZBERG L, BIRCH R, BUCKNER CD: The rationale for performing autologous peripheral blood stem cell transplants in community cancer centers. Oncologist (1998) 3 5):346-353.
33. LOKICH JJ, MOORE CL, ANDERSON NR: Comparison of costs for infusion versus bolus chemotherapy administration-Part two. Use of charges versus reimbursement for cost basis. Cancer (1996) 78 2):300-303.
34. LOKICH JJ, MOORE CL, ANDERSON NR: Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors-Part one. Model projections for cost based on charges. Cancer (1996) 78 2):294-299.
35. SCHULMAN KA, DORSAINVIL D, YABROFF KR et al.: Prospective economic evaluation accompanying a trial of GM-CSF/IL-3in patients undergoing autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. IL-3BMT Study Team. Bone Marrow Transplant. (1998) 21(6):607-614.
36. UYL-DE GROOT CA, RUTTEN FF: [Costs of autologous bone marrow transplantation in non-Hodgkin lymphoma and acute leukemia]. Ned. Tijdschr. Geneeskd (1994) 138(1):28-31.
37. WIRT DP, GILES FJ, OKEN MM, SOLAL-CELIGNY P, BECK JR: Cost-Effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma. Leuk. Lymphoma (2001) 40(5-6):565-579.
38. SWEETENHAM JW: Economics of stem cell transplantation for lymphoma: counting the cost of living. Br. J. Cancer (2000) 82 1):4-6.
39. HACKSHAW A, SWEETENHAM J, KNIGHT A: Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma? Br. J. Cancer (2004) 90 7):1302-1305.
40. ERRANTE D, VACCHER E, TIRELLI U: Are hematopoietic colony-stimulating factors useful in association with chemotherapy in the treatment of HIV-related non-Hodgkin's lymphomas? Ann. Oncol. (1996) 7(3):233-237.
41. TIRELLI U, VACCHER E: Economic and clinical evaluation of therapy of HIV-related non-Hodgkin's lymphoma with chemotherapy and granulocyte colony-stimulating factor (G-CSF). Eur. J. Cancer (1994) 30A(10):1589-1590.
42. UYL-DE GROOT CA, HUIJGENS PC, RUTTEN FF: Colony-stimulating factors and peripheral blood progenitor cell transplantation. Benefits and costs. Pharmacoeconomics (1996) 10(1):23-35.
43. WATERS TM, BENNETT CL, PAJEAU TS et al.: Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: what do we know? Bone Marrow Transplant. (1998) 21 7):641-650.
44. SIMNETT SJ, STEWART LA, SWEETENHAM J, MORGAN G, JOHNSON PW: Autologous stem cell transplantation for malignancy: a systematic review of the literature. Clin. Lab. Haematol. (2000) 22(2):61-72.
45. JOHNSON PW, SIMNETT SJ, SWEETENHAM JW, MORGAN GJ, STEWART LA: Bone marrow and peripheral blood stem cell transplantation for malignancy. Health Technol. Assess. (1998) 2(8):1-187.
46. HILLNER BE, SMITH TJ, DESCH CE: Cost-effective use of autologous bone marrow transplantation: few answers, many questions, and suggestions for future assessments. Pharmacoeconomics (1994) 6 2):114-126.
47. BEARD SM, WALL L, GAFFNEY L, SAMPSON F: Aggressive non-Hodgkin's lymphoma: economics of high-dose therapy. Pharmacoeconomics (2004) 22(4):207-224.
48. WAKE B, HYDE C, BRYAN S et al.: Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation. Health Technol. Assess. (2002) 6(3):1-85.
49. SWEETENHAM J, HIEKE K, KERRIGAN M et al.: Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma. in the U.K. Br. J. Haematol. (1999) 106(1):47-54.
50. TOLLEY K, MORGAN G, CARTWRIGHT R, WILLIAMS R: Economic aspects of non-Hodgkin's lymphoma. Office of Health Economics, London, UK (1998).
51. UYL-DE GROOT CA, HAGENBEEK A, VERDONCK LF, LOWENBERG B, RUTTEN FF: Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL). Bone Marrow Tansplant. (1995) 16 3):463-470.
52. UYL-DE GROOT CA, OKHUIJSEN SY, HAGENBEEK A et al.: Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in the Netherlands. Bone Marrow Transplant. (1995) 15:605-610.
53. BENNETT CL, ARMITAGE JL, ARMITAGE GO et al.: Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991. J. Clin. Oncol. (1995) 13(4):969-973.
54. DRANITSARIS G, SUTCLIFFE SB: Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma. Leuk. Lymphoma (1995) 17 1-2):139-145.
55. ZAGONEL V, BABARE R, MEROLA MC et al.: Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. Ann. Oncol. (1994) 5(Suppl. 2):127-132.
56. DRANITSARIS G, ALTMAYER C, QUIRT I: Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphoma. Pharmacoeconomics (1997) 11(6):566-577.
57. ZAIDI Y, CLARKE C, HUTCHINSON RM: CHOP/ABMT is less cost effective than CHOP alone in intermediate and high grade malignant non-Hodgkin's lymphoma (NHL) - single centre results. Bone Marrow Transplant. (1996) 17:S46.
58. VOGELSANG GB, MANCUSO AK, PURCELL WT: Cost-effectiveness of rituximab as standard of care in diffuse large B-cell lymphoma. Proc. Am. Soc. Clin. Oncol. (2003) 22:560.
59. NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE: Rituximab for aggressive non-Hodgkin's lymphoma. Abba Litho Sales Limited, London, UK (2003).
60. HAMBLIN T, BEST JH, HORNBERGER J, MORRIS J: Cost-effectiveness of Rituximab in treatment of diffuse large B-cell lymphoma. Br. J. Haematol. (2002) 117(59):a170.
61. COIFFIER B, BEST JH, OMNES LF, HORNBERGER JC: Cost-effectiveness of rituximab in treatment of diffuse large B-cell lymphoma. Oncology (2002) 16(3 Suppl. 2):3586.
62. NATIONAL HORIZON SCANNING CENTRE: Rituximab for aggressive B-cell lymphoma. Birmingham: National Horizon Scanning Centre (NHSC) (2002) 5:1-5.
63. BEARD SM, LORIGAN PC, SAMPSON FC: The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma. Br. J. Cancer (2000) 82(1):81-84.
64. MESSORI A, BONISTALLI L, COSTANTINI M, ALTERINI R: Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant. (1997) 19(3):275-281.
65. MAZZA P, SECONDO E, PALAZZO G et al.: Costs of high-dose salvage therapy and blood stem cell transplantation for resistant-relapsed malignant lymphomas in a southern Italian hospital. Haematologica (1999) 84(2):142-149.
66. VAN AGTHOVEN M, VELLENGA E, FIBBE WE, KINGMA T, UYL-DE GROOT CA: Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. A prospective randomised trial. Eur. J. Cancer (2001) 37(14):1781-1789.
67. MCKELVEY EM, GOTTLIEB JA, WILSON HE et al.: Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer (1976) 38(4):1484-1493.
68. VAN AGTHOVEN M, FABER LM, UYL-DE GROOT CA et al.: Cost analysis of CHOP (-like) chemotherapy regimens for patients with newly diagnosed aggressive non-Hodgkin's lymphoma. Eur. J. Haematol. (2002) 69(4):213-220.
69. FABER LM, VAN AGTHOVEN M, UYL-DE GROOT CA, LOWENBERG B, HUIJGENS PC: [Diagnosis and treatment of non-Hodgkin lymphoma in Netherlands: variation in guidelines and in practice]. Ned. Tijdschr. Geneeskd (2000) 144(25):1223-1227.
70. BOBEY N, WOODMAN RC: Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF). Clin. Invest. Med. (1998) 21(2):63-70.
71. SOUETRE E, QING W: Economic analysis of lenograstim in the correction of neutropenia following chemotherapy for non-Hodgkin's lymphoma. Pharmacoeconomics (1994) 6(Suppl.2):S36-S43.
72. DOORDUIJN JK, VAN DER HOLT B, VAN IMHOFF GW et al.: Randomized trial of CHOP versus CHOP plus Granulocyte Colony-Stimulating Factor (G-CSF) in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin. Oncol. (2003) 15(21):3041-3050.
73. GIANNI AM, BREGNI M, SIENA S et al.: High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N. Engl. J. Med. (1997) 336(18):1290-1297.
74. KLUIN-NELEMANS HC, ZAGONEL V, ANASTASOPOULOU A et al.: Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized Phase III EORTC study. J. Natl. Cancer Inst. (2001) 93(1):22-30.
75. VERDONCK LF, VAN PUTTEN WL, HAGENBEEK A et al.: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N. Engl. J. Med. (1995) 332 16):1045-1051.
76. HAIOUN C, LEPAGE E, GISSELBRECHT C et al.: Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. (1994) 12(12):2543-2551.
77. SANTINI G, SALVAGNO L, LEONI P et al.: VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J. Clin. Oncol. (1998) 16(8):2796-2802.
78. HAIOUN C, LEPAGE E, GISSELBRECHT C et al.: Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. (1997) 15(3):1131-1137.
79. HAIOUN C, LEPAGE E, GISSELBRECHT C et al.: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2protocol-a groupe d'Etude des lymphomes de l'Adulte study. J. Clin. Oncol. (2000) 18(16):3025-3030.
80. COIFFIER B, LEPAGE E, BRIERE J et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. (2002) 346 4):235-242.
81. MOUNIER N, BRIERE J, GISSELBRECHT C et al.: Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffise large B-cell lymphoma (DLBCL). Blood (2003) 101(11):4279-4284.
82. HABERMANN TM, WELLER EA, MORRISON VA et al.: Phase III trial of rituximab-CHOP (R-CHOP) versus CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Blood (2003) 102(11):8 [Abstract].
83. LISTER TA: Who should receive myeloablative therapy for lymphoma? N. Engl. J. Med. (2004) 350(13):1277-1278.
84. PHILIP T, GUGLIELMI C, HAGENBEEK A et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N. Engl. J. Med. (1995) 333(23):1540-1545.
85. SHIPP MA, ABELOFF MD, ANTMAN KH et al.: International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. Ann. Oncol. (1999) 10(1):13-19.
86. BAROSI G, MARCHETTI M, ALESSANDRINO P et al.: A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant. (1999) 23 7):719-725.
87. FAUCHER C, LE CORROLLER AG, BLAISE D et al.: Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness. Bone Marrow Transplant. (1994) 14(6):895-901.
88. AGER S, SCOTT MA, MAHENDRA P et al.: Peripheral blood stem cell transplantation after high-dose therapy in patients with malignant lymphoma: a retrospective comparison with autologous bone marrow transplantation. Bone Marrow Transplant. (1995) 16 1):79-83.
89. WORONOFF-LEMSI MC, ARVEUX P, LIMAT S, DECONINCK E, MOREL P, CAHN JY: Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients. Bone Marrow Transplant. (1997) 20 11):975-982.
90. HARTMANN O, LE CORROLLER AG, BLAISE D et al.: Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann. Intern. Med. (1997) 126(8):600-607.
91. SMITH TJ, HILLNER BE, SCHMITZ N et al.: Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J. Clin. Oncol. (1997) 15(1):5-10.
92. UYL-DE GROOT CA, OSSENKOPPELE GJ, BUIJT I, HUIJGENS PC: Costs of peripheral blood progenitor cell transplantation using whole blood mobilised by filgrastim as compared with autologous bone marrow transplantation in non-Hodgkin's lymphoma. Pharmacoeconomics (1999) 15(3):305-311.
93. JERJIS S, CROOCKEWIT S, MUUS P, SCHAAP N, PREIJERS F, DE WITTE T: Cost analysis of autologous peripheral stem cell transplantation versus autologous bone marrow transplantation for patients with non Hodgkin's lymphoma and acute lymphoblastic leukaemia. Leuk. Lymphoma (1999) 36(1-2):33-43.
94. LE CORROLLER AG, FAUCHER C, AUPERIN A et al.: Autologous peripheral blood progenitor-cell transplantation versus autologous bone marrow transplantation for adults and children with non-leukaemic malignant disease. A randomised economic study. Pharmacoeconomics (1997) 11(5):454-463.
95. UYL-DE GROOT CA, RICHEL DJ, RUTTEN FF: Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); a less costly alternative to autologous bone marrow transplantation. Eur. J. Cancer (1994) 30A(11):1631-1635.
96. UYL-DE GROOT CA, OSSENKOPPELE GJ, BUIJT I, HUIJGENS PC: Stem cell transplantations in patients with malignant lymphoma: costs in a Dutch university hospital in the period 1984-1995. J. Hematother. Stem Cell Res. (1999) 8(6):619-625.
97. MEISENBERG BR, FERRAN K, HOLLENBACH K, BREHM T, JOLLON J, PIRO LD: Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplant. (1998) 21 9):927-932.
98. TARELLA C, CASTELLINO C, LOCATELLI F et al.: G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplant. (1998) 21 4):401-407.
99. LEE SM, RADFORD JA, DOBSON L et al.: Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. Br. J. Cancer (1998) 77(8):1294-1299.
100. SOUETRE E, QING W, PENELAUD PF: Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantation. Eur. J. Cancer (1996) 32A 7):1162-1165.
101. LUCE BR, SINGER JW, WESCHLER JM et al.: Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer: an economic analysis of a randomised, double-blind, placebo-controlled trial. Pharmacoeconomics (1994) 6(1):42-48.
102. MCQUAKER IG, HUNTER AE, PACEY S, HAYNES AP, IQBAL A, RUSSELL NH: Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J. Clin. Oncol. (1997) 15(2):451-457.
103. BENNETT CL, ARMITAGE JL, LESAGE S, GULATI SC, ARMITAGE JO, GORIN NC: Economic analyses of clinical trials in cancer: are they helpful to policy makers? Stem Cells (1994) 12(4):424-429.
104. BENNETT CL, GEORGE SL, VOSE JM et al.: Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of Phase III clinical trials. Stem Cells (1995) 13(4):414-420.
105. STOCKERL-GOLDSTEIN KE, REDDY SA, HORNING SF et al.: Favorable treatment outcome in non-Hodgkin's lymphoma patients with 'poor' mobilization of peripheral blood progenitor cells. Biol. Blood Marrow Transplant. (2000) 6(5):506-512.
106. LIMAT S, WORONOFF-LEMSI MC, MILPIED N et al.: Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in front-line therapy. Eur. J. Cancer (2000) 36 18):2360-2367.
107. LIMAT S, WORONOFF-LEMSI MC, DECONINCK E et al.: Cost-effectiveness of CD34+ dose in peripheral blood progenitor cell transplantation for non-Hodgkin's lymphoma patients: a single centre study. Bone Marrow Transplant. (2000) 25(9):997-1002.
108. SCHULMAN KA, BIRCH R, ZHEN B, PANIA N, WEAVER CH: Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J. Clin. Oncol. (1999) 17(4):1227.
109. HEROLD M, SACCHI S, HIEKE K: The cost of treating relapsed indolent non-Hodgkin's lymphoma in an international setting: retrospective analysis of resource use. Haematologica (2002) 87 7):719-729; discussion 729.
110. HEROLD M, HIEKE K: Costs of toxicity during chemotherapy with CHOP, COP/CVP, and fludarabine. Eur. J. Health Econ. (2002) 3 166-172.
111. HEROLD M, HIEKE K: Costs of drug delivery for CHOP, COP/CVP, and Fludarabine: an international assessment. Value in Health (2003) 6(2):167-174.
112. GOLDMAN DP, BERRY SH, MCCABE MS et al.: Incremental treatment costs in national cancer institute-sponsored clinical trials. JAMA (2003) 289(22):2970-2977.
113. PEPPERCORN JM, WEEKS JC, COOK EF, JOFFE S: Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet (2004) 363 9405):263-270.
114. MAARTENSE E, HERMANS J, KLUIN-NELEMANS JC et al.: Elderly patients with non-Hodgkin's lymphoma: population-based results in The Netherlands. Ann. Oncol. (1998) 9(11):1219-1227.
115. DE RIJKE JM, SCHOUTEN LJ, SCHOUTEN HC, JAGER JJ, KOPPEJAN AG, VAN DEN BRANDT PA: Age-specific differences in the diagnostics and treatment of cancer patients aged 50years and older in the province of Limburg, The Netherlands. Ann. Oncol. (1996) 7(7):677-685.
116. SONNEVELD P, HUIJGENS PC, HAGENBEEK A: [Dose reduction is not recommended for elderly patients undergoing chemotherapy for non-Hodgkin lymphoma]. Ned. Tijdschr. Geneeskd (1999) 143(8):418-419.
117. ANNEMANS L, MOEREMANS K, LAMOTTE M et al.: Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk. Lymphoma (2003) 44(1):77-83.
118. ANNEMANS L, MOEREMANS K, LAMOTTE M et al.: Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support. Care Cancer (2003) 11(4):249-257.
119. GHIELMINI M, SCHMITZ SF, COGLIATTI SB et al.: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood (2004) 103(12):4416-4423.
120. SCHRAG D: The price tag on progress-chemotherapy for colorectal cancer. N. Engl. J. Med. (2004) 351(4):317-319.